Morgan Stanley Raises UiPath (NYSE:PATH) Price Target to $25.00

UiPath (NYSE:PATH) had its target price raised by Morgan Stanley from $17.00 to $25.00 in a research report report published on Thursday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the healthcare company’s stock.

Several other research analysts have also recently issued reports on the stock. Wells Fargo & Company raised their target price on shares of UiPath from $18.00 to $20.00 and gave the stock an equal weight rating in a report on Friday, December 1st. Canaccord Genuity Group raised their target price on shares of UiPath from $27.00 to $30.00 and gave the stock a buy rating in a report on Friday. BMO Capital Markets raised their price target on UiPath from $19.00 to $24.00 and gave the stock a market perform rating in a research note on Friday, December 1st. Scotiabank initiated coverage on UiPath in a research note on Wednesday, February 21st. They issued a sector perform rating for the company. Finally, Mizuho raised their price target on UiPath from $18.00 to $22.00 and gave the stock a neutral rating in a research note on Friday, December 1st. Nine analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, UiPath presently has an average rating of Hold and an average target price of $27.13.

UiPath Stock Up 1.4 %

Shares of UiPath stock traded up $0.32 on Thursday, hitting $23.07. The stock had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. UiPath has a one year low of $12.38 and a one year high of $27.87. The stock has a market cap of $13.06 billion, a price-to-earnings ratio of -135.46 and a beta of 0.97. The stock’s 50-day simple moving average is $23.52 and its two-hundred day simple moving average is $20.70.

Insider Transactions at UiPath

In other news, CFO Ashim Gupta sold 16,000 shares of UiPath stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $22.47, for a total value of $359,520.00. Following the completion of the transaction, the chief financial officer now owns 103,505 shares of the company’s stock, valued at approximately $2,325,757.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Rich Wong sold 200,000 shares of UiPath stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $23.12, for a total value of $4,624,000.00. Following the completion of the sale, the director now directly owns 429,418 shares in the company, valued at approximately $9,928,144.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Ashim Gupta sold 16,000 shares of UiPath stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $22.47, for a total value of $359,520.00. Following the completion of the sale, the chief financial officer now owns 103,505 shares of the company’s stock, valued at $2,325,757.35. The disclosure for this sale can be found here. Insiders sold a total of 411,000 shares of company stock valued at $9,418,670 in the last quarter. 31.03% of the stock is owned by insiders.

Institutional Investors Weigh In On UiPath

Several large investors have recently bought and sold shares of PATH. Raymond James Financial Services Advisors Inc. increased its holdings in UiPath by 3.8% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 40,993 shares of the healthcare company’s stock worth $885,000 after buying an additional 1,506 shares in the last quarter. MetLife Investment Management LLC bought a new stake in shares of UiPath during the 1st quarter valued at about $184,000. BlackRock Inc. grew its stake in shares of UiPath by 1.9% during the 1st quarter. BlackRock Inc. now owns 5,316,635 shares of the healthcare company’s stock valued at $114,786,000 after purchasing an additional 99,242 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of UiPath during the 1st quarter valued at about $534,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of UiPath during the 1st quarter valued at about $259,000. 59.04% of the stock is currently owned by institutional investors.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.